Ischemic stroke is a major cause of death and disabilities worldwide, and it has been long hoped that improved understanding of relevant injury mechanisms would yield targeted neuroprotective therapies. While Ca 2+ overload during ischemia-induced glutamate excitotoxicity has been identified as a major contributor, failures of glutamate targeted therapies to achieve desired clinical efficacy have dampened early hopes for the development of new treatments. However, additional studies examining possible contributions of Zn 2+ , a highly prevalent cation in the brain, have provided new insights that may help to rekindle the enthusiasm. In this review, we discuss both old and new findings yielding clues as to sources of the Zn 2+ that accumulates in many forebrain neurons after ischemia, and mechanisms through which it mediates injury. Specifically, we highlight the growing evidence of important Zn 2+ effects on mitochondria in promoting neuronal injury. A key focus has been to examine Zn 2+ contributions to the degeneration of highly susceptible hippocampal pyramidal neurons. Recent studies provide evidence of differences in sources of Zn 2+ and its interactions with mitochondria in CA1 versus CA3 neurons that may pertain to their differential vulnerabilities in disease. We propose that Zn 2+ -induced mitochondrial dysfunction is a critical and potentially targetable early event in the ischemic neuronal injury cascade, providing opportunities for the development of novel neuroprotective strategies to be delivered after transient ischemia.
Ischemic Stroke: The Role of Ca

2+
Ischemic stroke is a leading cause of disability and death worldwide, reflecting the extreme sensitivity of brain to even brief (several minutes) disruption of blood flow. Despite extensive efforts to understand the basis of this unique vulnerability with the aim of developing neuroprotective interventions, attempts to date have failed, with the maintenance and prompt restoration of perfusion being the only presently available therapeutic approach.
Considerable evidence implicates a role for "excitotoxicity" (neuronal damage triggered by excessive release of the excitatory neurotransmitter glutamate) occurring in conditions including ischemia, prolonged seizures and trauma. Excitotoxic mechanisms have been extensively investigated, and a critical early finding was that brief strong activation of highly Ca 2+ permeable N-methyl-daspartate (NMDA) type glutamate receptors (NMDAR) results in delayed Ca 2+ -dependent neurodegeneration (Choi 1987; Choi and others 1988) . After the brief exposure, intracellular Ca 2+ levels recover for a period of time before undergoing a sharp and sustained rise (termed "Ca 2+ deregulation") that is strongly correlated with cell death (Randall and Thayer 1992) .
It is also apparent that oxidative mechanisms contribute to the neuronal injury, induced after production of reactive oxygen species (ROS; including superoxide and nitric oxide) (Lafon-Cazal and others 1993; Sattler and others 1999) .
Mitochondria have been implicated as important targets of Ca 2+ effects. Ca 2+ enters mitochondria through a specific channel (the mitochondrial Ca 2+ uniporter, MCU), and under normal circumstances, physiological mitochondrial Ca 2+ rises help to regulate mitochondrial metabolic function by matching ATP production to need (Nicholls and Budd 2000) . Mitochondria are also important buffers of large cytosolic Ca 2+ loads (Wang and Thayer 1996; White and Reynolds 1997) . However, with excess accumulation, Ca 2+ can disrupt mitochondrial function, with effects including increased superoxide production (Dugan and others 1995; Reynolds and Hastings 1995) and opening of a large conductance inner membrane channel (the mitochondrial permeability transition pore; mPTP), that can lead to mitochondrial swelling and the release of cytochrome C and other pro-apoptotic peptides (Nicholls and Budd 2000) . Recent studies have also demonstrated the importance of another distinct mechanism of excitotoxic superoxide generation, via Ca 2+ -dependent activation of the superoxide-generating cytosolic enzyme NADPH oxidase (NOX) (Brennan and others 2009; Clausen and others 2013) , and it is likely that depending on conditions both sources can contribute.
However, despite considerable early hope and some promising results in animals, use of NMDAR antagonists (to prevent Ca 2+ -mediated injury and deregulation) have yielded little benefit in human studies (Hoyte and others 2004; Ikonomidou and Turski 2002) , necessitating a further search for new targets yielding better efficacy.
Zn
2+ : A Distinct Ionic Contributor to Brain Injury
Zn 2+ is a critical and highly prevalent cation in all tissues. It is particularly prevalent in brain, which has an overall Zn 2+ content estimated to be 100 to 200 µM and is especially high in certain limbic and forebrain regions, including hippocampus, amygdala, and cortex (Frederickson 1989) . Despite the high total Zn 2+ , virtually all of it is bound or sequestered; while precise measurements are difficult (as it can bind numerous ligands with a wide range of affinities), it is agreed that free intracellular Zn 2+ levels are subnanomolar (Colvin and others 2010; Maret 2015) . Reflecting its importance in all tissues, there are two families of transporters (with >20 variants identified to date) dedicated to movement of Zn 2+ between compartments, with the Zrt-, Irt-like protein (ZIP) family moving Zn 2+ into cytosol, and the Zn 2+ transporter (ZnT) family moving Zn 2+ from cytosol out of the cell or into subcellular compartments (Kambe and others 2014) . In neurons, most (~ 90%) of the Zn 2+ is bound to or associated with proteins, and it is an integral component of numerous enzymes, transcription factors and structural proteins (Frederickson 1989 ).
Synaptic Zn
2+ : A Modulator of Neurotransmission and Contributor to Injury
A distinct and critical pool of brain Zn 2+ is that which is sequestered within presynaptic vesicles of some excitatory neurons. This pool of free or loosely bound Zn 2+ is visualized by histochemical procedures like Timm's silver sulfide staining or labeling with Zn 2+ -sensitive fluorescent dyes and is often referred to as chelatable or "histochemically reactive" Zn 2+ (Frederickson 1989; Frederickson and others 1992) . This Zn 2+ has a distinctive distribution, generally corresponding with areas of greatest total Zn 2+ ; high levels are found in hippocampus (particularly the dentate granule cells and their "mossy fiber" projections, accounting for the distinctive appearance of hippocampus after Timm's staining; see Fig. 1A ), as well as in cortex and amygdala. In these neurons, the Zn 2+ appears to be loaded into vesicles at millimolar concentrations by the vesicular Zn 2+ transporter, ZnT3 (Cole and others 1999) . It is further evident that this Zn 2+ is coreleased with glutamate on stimulation (Assaf and Chung 1984; Howell and others 1984; Sloviter 1985) , and peak levels at synapses may reach into the 100 µM range with , accounting for the dark labeling of this pathway on Timm's silver sulfide staining (A). Note the loss of synaptic Zn 2+ labeling after ischemia (B), resulting from release of this synaptic Zn 2+ .
strong activation (Ueno and others 2002; Vogt and others 2000) , constituting about a 10,000-fold increase over physiologic resting level of extracellular Zn 2+ (Frederickson and others 2006) .
The identification of populations of forebrain excitatory neurons containing substantial quantities of presynaptic vesicular Zn 2+ begs understanding of the actions and effects of synaptically released Zn 2+ . While much is not known, Zn 2+ has complex effects on extracellular receptors, antagonizing NMDAR currents via both voltage-dependent and -independent mechanisms; electrophysiological studies have demonstrated Zn 2+ release from mossy fibers to provide tonic inhibition of NMDAR on CA3 pyramidal neurons (Vogt and others 2000) . In addition, Zn 2+ has effects on GABA and glycinergic receptors, as well as on a Zn 2+ sensing G-protein linked metabotropic receptor, and synaptic Zn 2+ likely has roles in forms of synaptic plasticity (Sensi and others 2011) .
Observations that ischemia, prolonged seizures and brain trauma resulted in loss of chelatable Zn 2+ labeling in presynaptic pools (most evident in the mossy fibers) (see Fig. 1B ), and its appearance in somata of injured neurons led to the suggestion that synaptic Zn 2+ release and its translocation through channels into postsynaptic neurons contributed to their degeneration in these conditions (Frederickson and others 1989; Suh and others 2000; Tonder and others 1990) . Indeed, this idea was markedly strengthened by observations that application of an extracellular Zn 2+ chelator decreased both the postsynaptic Zn 2+ accumulation and subsequent neurodegeneration (Calderone and others 2004; Koh and others 1996; Yin and others 2002) .
Paralleling observations of neuronal Zn 2+ accumulation after seizures or ischemia in vivo, studies in neuronal culture models documented the potent toxic effects of Zn 2+ and sought to examine its mechanisms. One early aim was to identify the routes through which synaptically released Zn 2+ can enter postsynaptic neurons to trigger injury. These studies found Zn 2+ to permeate three distinct channels through which Ca 2+ also permeates: (1) NMDAR (Koh and Choi 1994) , (2) L-type voltage-gated Ca 2+ channels (VGCC) (Freund and Reddig 1994; Kerchner and others 2000; Weiss and others 1993) , and (3) atypical Ca 2+ permeable AMPA type glutamate receptors ("Ca-AMPAR"); whereas most AMPA receptors are Ca 2+ impermeable, these lack the GluA2 subunit in their tetrameric structure, and are only present in substantial numbers on small subpopulations of neurons. We found these Ca-AMPAR to be highly Zn 2+ permeable (Jia and others 2002; Yin and Weiss 1995 (Sensi and others 1999) .
While brief moderate Zn 2+ exposures to depolarized neurons resulted in sufficient Zn 2+ entry through VGCC to trigger extensive degeneration over the subsequent day (Weiss and others 1993) , several considerations led us to believe that entry through Ca-AMPAR might be of particular importance. First, despite their selective expression (in contrast to the VGCC, they are only present in large numbers on ~13% of neurons in cortical cultures and preferentially found in dendrites of some pyramidal neurons) (Lerma and others 1994; Ogoshi and Weiss 2003; Sensi and others 1999; Yin and others 1994; Yin and others 1999) accumulation has been found to trigger a delayed increase in numbers of Ca-AMPAR in many forebrain neurons 2 to 3 days after transient ischemia (due to decreased expression of GluA2), a factor that likely contributes to delayed neurodegeneration (Calderone and others 2004; Gorter and others 1997) . Indeed, supporting the significance of this route, a Ca-AMPAR antagonist attenuated Zn 2+ accumulation and injury both in a slice model of acute ischemia (Yin and others 2002) , and when delivered late after transient global ischemia in vivo (Noh and others 2005) . However, this does not mean VGCC are unimportant. Although VGCC are not concentrated specifically at synapses, entry through this route would likely occur under pathologic conditions in which extracellular Zn 2+ accumulation is accompanied by widespread neuronal depolarization. Also, VGCC activity increases with age (Thibault and Landfield 1996) , possibly increasing the contribution of this route in aging populations most at risk of brain ischemia.
The generation of ZnT3 knockout mice, which are entirely lacking in chelatable presynaptic Zn 2+ (Cole and others 1999) (Maret 1995) . Zn 2+ binding to MTs is highly sensitive to environmental conditions, with metabolic aberrations associated with pathological conditions (specifically oxidative stress and acidosis) destabilizing binding, resulting in release of free Zn 2+ into cytosol (Jiang and others 2000; Maret 1995) . A seminal observation that simple application of a disulfide oxidant to cultured neurons was capable of causing cytosolic Zn 2+ rises that could trigger delayed neurodegeneration provided the first proof of principle that simple mobilization of Zn 2+ from intracellular buffers could result in neurodegeneration (Aizenman and others 2000) . A subsequent study overexpressing MT-III found that depending on conditions it could have divergent effects, either buffering excess Zn 2+ that enters the cell (and thereby diminishing its toxic effects), or providing a source of injurious Zn 2+ mobilization, under conditions of oxidative stress (Malaiyandi and others 2004) .
Indeed, use of MT-III knockout mice (as well as double MT-III/ZnT3 knockouts) helped clarify the respective contributions of synaptic vs MT-III bound Zn 2+ in the kainate seizure model. In contrast to the increased Zn 2+ accumulation seen in ZnT3 knockouts in CA1 neurons, Zn 2+ accumulation and injury in MT-III knockouts were decreased in CA1, consistent with a dominant contribution of mobilization from MT-III. Conversely, these were increased in CA3 of MT-III knockouts, consistent with synaptic "translocation" predominating, with MT-III in CA3 serving a protective role by helping to buffer Zn 2+ entering the neurons (Lee and others 2003) .
Might these differences in sources of injurious Zn 2+ accumulation be a factor contributing to their differential disease susceptibilities, with CA3 neurons preferentially degenerating after recurrent limbic seizures (associated with repetitive firing of the Zn 2+ rich mossy fibers) and CA1 neurons undergoing delayed degeneration after transient ischemia (BenAri and others 1980; Sugawara and others 1999 . Furthermore, using a high affinity Zn 2+ indicator in combination with a low affinity Ca 2+ indicator, it became possible to simultaneously track changes in both ions (Devinney and others 2005) . We used this approach to simultaneously track changes in both Zn 2+ and Ca 2+ in single pyramidal neurons in hippocampal slices subjected to oxygen glucose deprivation (OGD) (see Fig. 2A ). Interestingly, we found that cytosolic Zn 2+ rises both preceded and contributed to the onset of terminal Ca 2+ deregulation events, which still occurred but were significantly delayed by the presence of a Zn 2+ chelator (see Fig. 2B ) (Medvedeva and others 2009 ). This provided new evidence that Zn 2+ accumulation might be an early event in the ischemic injury cascade, the appropriate targeting of which might provide therapeutic benefit. As discussed further below, clues from this and other early studies suggested that mitochondria might be an important target for these early Zn 2+ effects (see Fig. 2C ).
Mitochondria: A Critical Target of Zn
2+
Paralleling studies of Ca 2+ , studies over several decades have highlighted ways in which Zn 2+ affects mitochondrial function. Below, we review the evolution of these data, leading up to our proposition that mitochondrial Zn 2+ accumulation may be an important early step in the ischemic injury cascade of many neurons. Specifically, as it occurs upstream from terminal Ca 2+ deregulation, its targeting may provide benefits distinct from those provided by attenuation of Ca 2+ entry (via NMDAR blockade).
Isolated Mitochondria: Evidence of Potent Zn 2+ Effects
A number of studies dating back more than 50 years have found that Zn 2+ can enter mitochondria, inducing effects including swelling, and inhibition of respiration with high potency (Brierley 1967; Skulachev and others 1967) . Over the subsequent decades, with growing awareness that Zn 2+ is a pathophysiologically important ion that contributes to neuronal injury, there has been an increasing interest in determining how Zn 2+ impacts mitochondria. Zn 2+ was found to enter mitochondria specifically through the MCU (Saris and Niva 1994) , and to trigger opening of the mPTP (Wudarczyk and others 1999) . Other studies found potent (submicromolar) Zn 2+ inhibition of the bc1 complex of the electron transport chain and of the tricarboxylic acid cycle α-ketoglutarate dehydrogenase enzyme complex (Brown and others 2000; Link and von Jagow 1995) . Highlighting the complexity of Zn 2+ effects on mitochondria, we found low (submicromolar) exposures to induce loss of mitochondrial membrane potential (ΔΨ mito ), decreased ROS production and increased O 2 consumption (consistent with uncoupling of the electron transport from ATP synthesis), while slightly higher levels increased ROS generation and decreased O 2 consumption (consistent with inhibition of electron transport) (Sensi and others 2003) . A subsequent study reported Zn 2+ , after entry through the MCU, to induce irreversible inhibition of major thiol oxidoreductase enzymes involved in energy production and antioxidant defense, an effect that appeared to be linked to mPTP opening (Gazaryan and others 2007) . Thus, it is apparent that Zn 2+ effects on mitochondria are complex and a better definition of its mechanisms and how its entry is regulated by the MCU are rich areas for further investigation. Yet, the potency of its effects, taken together with the high levels of Zn 2+ present in neurons, highlight the strong potential for Zn 2+ to contribute to mitochondrial dysfunction in disease.
Cell Culture Studies: Neuronal Zn 2+ Entry Results in Mitochondrial Accumulation and Dysfunction Contributing to Cell Death
Culture studies permit investigation of Zn 2+ effects in the neuronal environment, bringing us a step closer to understanding possible effects in diseases like ischemia. Above, we introduced studies examining routes through which synaptic Zn 2+ could enter neurons and reported evidence for particularly rapid entry through selectively expressed Ca-AMPAR, with slower entry through VGCC. We subsequently examined effects of this Zn 2+ entry, and found brief Ca-AMPAR activation, in the presence of 100 to 300 µM Zn 2+ , to induce rapid loss of ΔΨ mito and ROS generation that persisted for at least an hour after the exposure, were both present during the exposure, the ROS production was significantly greater than with Zn 2+ alone, again indicating synergistic effects of these ions (Sensi and others 1999; Sensi and others 2000) .
In other studies, we induced smaller Zn 2+ loads, via similar brief Zn 2+ exposures under depolarizing conditions, to trigger entry through VGCC (rather than Ca-AMPAR). Although still causing considerable delayed neurotoxicity (Weiss and others 1993) , these exposures did not cause the acute ROS generation and loss of ΔΨ mito seen with rapid entry through Ca-AMPAR (Sensi and others 1999; Sensi and others 2000) . This, along with similar findings by others, have led to questions as to the likelihood that mitochondria constitute important targets of Zn 2+ effects in disease (Pivovarova and others 2014). However, despite the absence of rapid ROS production, these brief episodes of Zn 2+ entry through VGCC had distinct and long-lasting effects on mitochondria, with low (50-100 µM) exposures resulting in Zn 2+ accumulation within mitochondria persisting for at least 2 hours after the exposure along with partial loss of ΔΨ mito (Sensi and others 2002) ; similar brief exposures with 300 µM Zn 2+ (and 1.8 mM Ca 2+ ) triggered mitochondrial swelling, and delayed release of apoptotic mediators (cytochrome C and apoptosis inducing factor) (Jiang and others 2001), possibly consistent with more slowly evolving cell death occurring after these exposures.
Notably, cytosolic Zn 2+ accumulation results not only from entry of extracellular Zn 2+ , but also on mobilization from cytosolic pools like MT-III, and studies of the effects of strong cytosolic Zn 2+ mobilization alone also have found it to induce effects on mitochondria, contributing to loss of ΔΨ mito and delayed degeneration (BossyWetzel and others 2004; Sensi and others 2003) . In addition, recent studies have highlighted possible contributions of such Zn 2+ mobilization and consequent mitochondrial dysfunction to the Ca 2+ dependent excitotoxic injury cascade (Granzotto and Sensi 2015) . In pathologic conditions like ischemia or seizures, where synaptic Zn 2+ release and mobilization from cytosolic buffers both occur, it is likely that both sources contribute to mitochondrial dysfunction. Indeed, in cell culture studies we find evidence for synergistic impact on mitochondria, with even brief and quite low levels of Zn 2+ entry through VGCC (which alone had little or no acute effect on mitochondria), when combined with disrupted buffering (using DTDP [2,2′-dithiodipyridine] , that also by itself had little or no effect), resulting in dramatic potentiation of acute mitochondrial ROS generation and loss of ΔΨ mito , long lasting inhibition of mitochondrial respiration, and cell death (Clausen and others 2013; Ji and Weiss 2018) . Furthermore, although the presence of physiological Ca 2+ during the brief Zn 2+ exposure attenuated cytosolic Zn 2+ loading (due to competition with Zn 2+ for entry through VGCC), the effects on mitochondrial function and cell death were markedly enhanced, further highlighting the synergistic effects of these two ions. Indeed, the strong correlation between effects of disrupted buffering and presence of Ca 2+ on mitochondrial function with those on consequent cell death provide further support to the hypothesis that mitochondrial disruption contributes directly to Zn 2+ triggered neurotoxicity (Ji and Weiss 2018) .
Thus, these findings not only indicate the potency with which Zn 2+ accumulation in neurons can cause mitochondrial dysfunction, they further support the contention that during in vivo ischemia, even low level Zn 2+ entry from the extracellular space, when combined with impaired intracellular Zn 2+ buffering and mobilization from intracellular pools, has potential to powerfully disrupt mitochondrial function and contribute to subsequent neuronal injury.
Slice and In Vivo Studies Support Contributions of Mitochondrial Zn 2+ to Ischemic Neuronal Injury
Although the studies discussed above demonstrate that exogenously applied Zn 2+ can affect mitochondria and contribute to neuronal injury, this does not indicate that endogenous Zn 2+ actually does so in ischemia. However, recent studies in more pathophysiologically relevant ischemia models provide compelling evidence that mitochondria are indeed important targets of endogenous Zn 2+ effects. Specifically, in one study, addition of extracellular Zn 2+ chelators shortly after a transient episode of ischemia reduced the subsequent mitochondrial release of pro-apoptotic peptides (Calderone and others 2004) . In another in vivo study, Zn 2+ was found to accumulate in mitochondria within 1 hour after transient ischemia, contributing to the opening of large, multi-conductance outer membrane channels (Bonanni and others 2006) . However, whereas these studies demonstrate that Zn 2+ contributes to mitochondrial dysfunction after in vivo ischemia, they do not address therapeutically crucial questions including the source and time course of the Zn 2+ accumulation, and potential avenues for beneficial interventions.
To examine these issues, we have undertaken studies using hippocampal slice OGD models, a paradigm that models aspects of in vivo ischemia while permitting precise control of the microenvironment and detailed measurement of cellular responses. Our early studies in this model (see Fig. 2A and B) found cytosolic Zn 2+ rises to precede and contribute to the onset of delayed Ca 2+ deregulation and cell death during prolonged, lethal OGD (Medvedeva and others 2009), with evidence for early Zn 2+ entry into mitochondria. Subsequent studies provided strong evidence that Zn 2+ entry specifically through the MCU is a critical early step, triggering mitochondrial dysfunction (including ROS production) that contributes to the occurrence of acute Ca 2+ deregulation and degeneration of CA1 neurons (Fig. 2C) (Medvedeva and Weiss 2014) .
In further studies using this slice OGD model, we have compared the contributions and sources of Zn 2+ between CA1 and CA3 neurons (Medvedeva and others 2017) . First, we found that neuronal Zn 2+ accumulation contributes to a similar extent in both subdomains, with early Zn 2+ rises preceding Ca 2+ deregulation, and Zn 2+ chelation similarly delaying the onset of the terminal Ca 2+ deregulation in both regions. However, our studies using ZnT3 and MT-III knockout mice implicated distinct differences in the sources of the Zn 2+ underlying acute OGD induced injury. Paralleling the differences previously noted after prolonged in vivo seizures (Lee and others 2000; Lee and others 2003) , synaptic Zn 2+ release and its translocation largely through Ca-AMPAR dominated in CA3, and Zn 2+ mobilization from MT-III dominated in CA1 (see Fig. 3A ).
Because most opportunities for intervention are after reperfusion, we examined events occurring after sublethal episodes of OGD (which better model transient in vivo ischemia) and found evidence for substantial difference between CA1 and CA3 mitochondria in their handling of the Zn 2+ loads. In these studies, we terminated the OGD after the early Zn 2+ rises had occurred but shortly before the time of the terminal Ca 2+ deregulation, and in both regions, the cytosolic Zn 2+ rises gradually recovered, in part due to uptake into mitochondria via the MCU. However, at 1 hour after OGD, there was still considerable Zn 2+ retained within CA1 mitochondria, whereas in CA3 mitochondrial Zn 2+ loads recovered far more rapidly (generally within 20 minutes) (see Fig. 3B ) (Medvedeva and others 2017) . In light of the differential susceptibilities of CA1 versus CA3 neurons in disease, with CA1 neurons undergoing prominent delayed degeneration after transient ischemia, associated with mitochondrial swelling and release of cytochrome C (Sugawara and others 1999), might the persistent Zn 2+ accumulation within CA1 mitochondria be a trigger of events leading to the delayed degeneration of these neurons? Further elucidation of mitochondrial Zn 2+ interactions during and after ischemia in hippocampus as well as in other Zn 2+ rich areas of brain (including cortex) may reveal new therapeutic approaches and time windows for their delivery that may yield improved outcomes.
Neurodegeneration: The Culmination of Cascades of Injury-Promoting Events
Cell death is multistep process, occurring when a sequence of events leads to a state from which the cell cannot recover. As discussed above, ROS production has been strongly implicated as a trigger of the neurodegeneration occurring after excitotoxic Ca 2+ loading, and downstream events have been identified, including activation of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme involved in DNA repair, which becomes activated in response to ROS induced DNA damage. PARP utilizes NAD + as substrate, with strong activity leading to NAD + depletion, glycolytic and mitochondrial inhibition, and release of the apoptotic mediator, apoptosis inducing factor (AIF) (Kauppinen and Swanson 2007) . Paralleling these studies of Ca 2+ excitotoxicity, moderate Zn 2+ exposures have also been found to cause ROS production (in part due to delayed induction of NOX and neuronal nitric oxide synthase) (Kim and Koh 2002; Noh and Koh 2000) , resulting in PARP activation, 
: Possible Future Directions
In summary, studies at multiple levels of complexityranging from isolated mitochondria and dissociated neurons, to hippocampal slice and in vivo models of ischemia-indicate that Zn 2+ is likely to contribute to mitochondrial dysfunction, ROS generation, and neurodegeneration in ischemia (and may well do so in prolonged seizures and brain trauma as well). Furthermore, emerging evidence supports the notion that the Zn 2+ entry into mitochondria is an early event in the ischemic injury cascade (especially in hippocampal CA1), which, as it occurs upstream from onset of terminal Ca 2+ deregulation, may not be adequately targeted by simply slowing neuronal Ca 2+ entry (as via NMDAR blockade). We suggest that Zn 2+ accumulation in neuronal mitochondria is a targetable early event in the cell death cascade of CA1 and other populations of forebrain neurons; this idea merits further investigation and examination for therapeutic utility.
With strong and prolonged ischemia, mitochondrial Zn 2+ loading may result in rapid irreversible mitochondrial disruption and cell death (Medvedeva and others 2009; Medvedeva and Weiss 2014 ) (see Fig. 2 ). However, with milder or transient ischemia, mitochondrial Zn 2+ loading may contribute to the activation of downstream cell death pathways. Optimal interventions might well vary depending on the stage at which they are delivered. We believe that the targeting of specific events in the injury cascade has potential to yield benefit (see Fig. 4 2+ loading may also act upstream to more delayed apoptotic forms of injury, with Zn 2+ triggered mPTP opening (occurring up to several hours after the Zn 2+ load) resulting in mitochondrial disruption and release of apoptotic mediators like (cytochrome C and AIF), effects against which mPTP blockers (like cyclosporine A) might provide benefit. 4. Downstream injury pathways: As noted above, Zn 2+ signals have been found to contribute to delayed insertion of new ion channels that promote delayed neurodegeneration. Targeting of these channels (specifically Kv2.1 channels and Ca-AMPAR) may yield benefit from hours to several days after the episode ( In summary, accumulating evidence supports the notion that early mitochondrial Zn 2+ accumulation after ischemia contributes to mitochondrial dysfunction and may well be a critical triggering event for a number of neurodegenerative cascades. The targeting of these Zn 2+ triggered events in the post ischemic period has been largely unexplored, yet has potential to yield substantial benefit, and merits further study.
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